Biogen earnings, Revenue beat in Q3 – Biogen (NASDAQ:) reported on Tuesday third quarter that beat analysts’ forecasts and revenue that topped expectations. Biogen announced earnings per share of $4.77 on revenue of $2.51. Analysts polled by anticipated EPS of $4.14 on revenue of $2.47B. Biogen shares are down 13.16% from the beginning of the year and are trading … Read more

Biogen Risk/Reward is Upside Biased

© Reuters. By Sam Boughedda  Biogen (NASDAQ:) shares were upgraded to Buy from Hold, with the price target raised to $299 from $223 per share by Stifel analysts on Thursday. The analysts said the company’s shares have faded since the positive lecanemab data. In addition, they do worry about residual competitive/commercial risks in spite of … Read more

Today’s Most Important Upgrades, Prothena & Biogen Shares Surge on Positive Data By

© Reuters BofA Securities upgraded Prothena Corp (PRTA) to Buy from Neutral and raised its price target to $65.00 from $45.00 following Biogen’s and Eisai’s announced positive topline data from their anti-amyloid beta (Ab) antibody, lecanemab. Shares surged around 80% intra-day today. Baird upgraded Biogen (NASDAQ:) to Outperform from Neutral and raised its price target … Read more

‘Must Win,’ ‘Make or Break’: Biogen Could Stage a Massive Rally on Positive Clarity-AD Results

© Reuters. By Senad Karaahmetovic Ahead of the expected data from the CLARITY-AD pivotal trial of lecanemab in Alzheimer’s disease, a BMO analyst weighed in on potential outcomes and what they would mean for Biogen (NASDAQ:) shares. The analyst sees CLARITY-AD as a “must win,” “make or break” for the biotech giant. “Lecanemab either hits … Read more